The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
Open accessAbstract
BACKGROUND: Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead. We investigated the hypothesis that the addition of clopidogrel to aspirin would reduce the risk of vascular events in patients with atrial fibrillation. METHODS: A total of 7554 patients with atrial fibrillation who had an increased risk of stroke and for whom vitamin K-antagonist therapy was unsuitable were randomly assigned to receive clopidogrel (75 mg) or placebo, once daily, in addition to aspirin. The primary outcome was the composite of stroke, myocardial infarction, non-central nervous system systemic embolism, or death from vascular causes. RESULTS: At a median of 3.6 years of follow-up, major vascular events had occurred in 832 patients receiving clopidogrel (6.8% per year) and in 924 patients receiving placebo (7.6% per year) (relative risk with clopidogrel, 0.89; 95% confidence interval [CI], 0.81 to 0.98; P=0.01). The difference was primarily due to a reduction in the rate of stroke with clopidogrel. Stroke occurred in 296 patients receiving clopidogrel (2.4% per year) and 408 patients receiving placebo (3.3% per year) (relative risk, 0.72; 95% CI, 0.62 to 0.83; P<0.001). Myocardial infarction occurred in 90 patients receiving clopidogrel (0.7% per year) and in 115 receiving placebo (0.9% per year) (relative risk, 0.78; 95% CI, 0.59 to 1.03; P=0.08). Major bleeding occurred in 251 patients receiving clopidogrel (2.0% per year) and in 162 patients receiving placebo (1.3% per year) (relative risk, 1.57; 95% CI, 1.29 to 1.92; P<0.001). CONCLUSIONS: In patients with atrial fibrillation for whom vitamin K-antagonist therapy was unsuitable, the addition of clopidogrel to aspirin reduced the risk of major vascular events, especially stroke, and increased the risk of major hemorrhage. (ClinicalTrials.gov number, NCT00249873.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antiplatelet therapy increases bleeding risk, especially dual antiplatelet therapy (2.0% vs. 1.3% with antiplatelet monotherapy; P < 0.001), 433 with bleeding rates that are similar to those on OAC.354,362,431,434”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [433]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atrial fibrillation as an independent risk factor for stroke: the Framingham study
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.8.983 · Cited by 7,388
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Self-citationHart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67660-x · Cited by 1,858
Fuster, V., Rydén, L., Cannom, D. S., Crijns, H. J. G. M., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Heuzey, J. L., Kay, G. N., Lowe, J. E., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.009 · Cited by 1,161
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
Watson, T., Shantsila, E., & Lip, G. Y. H. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60040-4 · Cited by 1,124
Antithrombotic Therapy in Atrial Fibrillation
Singer, D. E., Albers, G. W., Dalen, J. E., Fang, M. C., Go, A. S., Halperin, J. L., Lip, G. Y. H., & Manning, W. J. (2008) · CHEST Journal · doi:10.1378/chest.08-0678 · Cited by 758
Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation
van Walraven, C., Hart, R. G., Singer, D. E., Laupacis, A., Connolly, S. J., Petersen, P., Koudstaal, P. J., Chang, Y., & Hellemons, B. S. P. (2002) · JAMA · doi:10.1001/jama.288.19.2441 · Cited by 715
Cannon, C. P., Battler, A., Brindis, R. G., Cox, J. L., Ellis, S. G., Every, N. R., Flaherty, J. T., Harrington, R. A., Krumholz, H. M., Simoons, M. L., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01702-8 · Cited by 673
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,000
Hydrogen sulfide donors: Therapeutic potential in anti-atherosclerosis
Zhang, H., Bai, Z., Zhu, L., Liang, Y., Fan, X., Li, J., Wen, H., Shi, T., Zhao, Q., & Wang, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112665 · Cited by 60
Mack, M. J., Head, S. J., Holmes, D. R., Ståhle, E., Feldman, T. E., Colombo, A., Morice, M., Unger, F., Ērglis, A., Stoler, R., et al. (2013) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2012.11.010 · Cited by 59
Tsadok, M. A., Jackevicius, C. A., Rahme, E., Humphries, K. H., & Pilote, L. (2015) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.114.001398 · Cited by 59
Steinhubl, S. R., Mehta, R. R., Ebner, G. S., Ballesteros, M. M., Waalen, J., Steinberg, G., Crocker, P. V., Felicione, E., Carter, C. T., Edmonds, S., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.02.011 · Cited by 59
Kosmidou, I., Liu, Y., Alu, M. C., Liu, M., Madhavan, M. V., Chakravarty, T., Makkar, R., Thourani, V. H., BIVIANO, A. B., Kodali, S., et al. (2019) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2019.06.001 · Cited by 59
Abraham, N., Noseworthy, P., Inselman, J., Herrin, J., Yao, X.-X., Sangaralingham, L., Cornish, G., Ngufor, C. G., & Shah, N. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.017 · Cited by 58
Kaneko, M., Tanigawa, T., Hashizume, K., Kajikawa, M., Tajiri, M., & Mueck, W. (2013) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rg-109 · Cited by 59
Old and new anticoagulant drugs: A minireview
Mannucci, P. M., & Franchini, M. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.539250 · Cited by 58
Shah, A., Shewale, A. R., Hayes, C. J., & Martin, B. C. (2016) · Stroke · doi:10.1161/strokeaha.115.012325 · Cited by 58
Non-Vitamin K Antagonist Oral Anticoagulants Do Not Increase Cerebral Microbleeds
Saito, T., Kawamura, Y., Sato, N., Kano, K., Takahashi, K., Asanome, A., Sawada, J., Katayama, T., & Hasebe, N. (2015) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2015.02.018 · Cited by 57
Pfeilschifter, W., Spitzer, D. E., Czech-Zechmeister, B., Steinmetz, H., & Foerch, C. (2011) · Stroke · doi:10.1161/strokeaha.110.604652 · Cited by 56
Ancrenaz, V., Daali, Y., Fontana, P., Besson, M. J., Samer, C. F., Dayer, P., & Desmeules, J. A. (2010) · Current Drug Metabolism · doi:10.2174/138920010794233521 · Cited by 57
Direct oral anticoagulants do not worsen traumatic brain injury after low-level falls in the elderly
Batey, M., Hecht, J. P., Callahan, C., & Wahl, W. L. (2018) · Surgery · doi:10.1016/j.surg.2018.05.060 · Cited by 57
Chatterjee, S., Sardar, P., Giri, J. S., Ghosh, J., & Mukherjee, D. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.01.030 · Cited by 56
Limone, B. L., Baker, W. L., Kluger, J., & Coleman, C. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062183 · Cited by 57
Marcucci, M., Iorio, A., Nobili, A., Tettamanti, M., Pasina, L., Marengoni, A., Salerno, F., Corrao, S., & Mannucci, P. M. (2010) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2010.07.014 · Cited by 55
Nagao, T., Inden, Y., Yanagisawa, S., Kato, H., Ishikawa, S., Okumura, S., Mizutani, Y., Ito, T., Yamamoto, T., Yoshida, N., et al. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.04.016 · Cited by 56
Caldeira, D., Cruz, I., Morgado, G., Stuart, B., Gomes, C., Martins, C., João, I., & Pereira, H. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-891 · Cited by 56
Grönberg, T., Hartikainen, J. E. K., Nuotio, I. O., Biancari, F., Ylitalo, A., & Airaksinen, J. K. E. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.01.024 · Cited by 56
Atrial platelet reactivity in patients with atrial fibrillation
Willoughby, S. R., Roberts-Thomson, R., Lim, H. S., Schultz, C., Prabhu, A., Sciscio, P. D., Wong, C. X. J., Worthley, M. I., & Sanders, P. (2010) · Heart Rhythm · doi:10.1016/j.hrthm.2010.01.042 · Cited by 55
Mariani, M. V., Magnocavallo, M., Straito, M., Piro, A., Severino, P., Iannucci, G., Chimenti, C., Mancone, M., Rocca, D. G. D., Forleo, G. B., et al. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02304-3 · Cited by 56
Field, T. S., & Hill, M. D. (2019) · Stroke · doi:10.1161/strokeaha.119.025334 · Cited by 55
Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation
Sinnaeve, P., Brueckmann, M., Clemens, A., Oldgren, J., Eikelboom, J. W., & Healey, J. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02464.x · Cited by 54
Camm, A. J., Pinto, F. J., Hankey, G. J., Andreotti, F., & Hobbs, F. D. R. (2015) · EP Europace · doi:10.1093/europace/euv068 · Cited by 54
Sandhu, R. K., Hohnloser, S. H., Pfeffer, M. A., Yuan, F., Hart, R. G., Yusuf, S., Connolly, S. J., McAlister, F. A., & Healey, J. S. (2015) · Stroke · doi:10.1161/strokeaha.114.007140 · Cited by 54
New Anticoagulant and Antiplatelet Agents: A Primer for the Gastroenterologist
Baron, T. H., Kamath, P. S., & McBane, R. D. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.05.020 · Cited by 53
Costantinides, F., Rizzo, R., Pascazio, L., & Maglione, M. (2016) · BMC Oral Health · doi:10.1186/s12903-016-0170-7 · Cited by 53
Weinberg, E. M., Palecki, J., & Reddy, K. R. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1679934 · Cited by 52
Hijazi, Z., Benz, A. P., Lindbäck, J., Alexander, J. H., Connolly, S. J., Eikelboom, J. W., Granger, C. B., Kastner, P., Lópes, R. D., Ziegler, A., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac632 · Cited by 52
“Outcomes Outcome definitions (ischaemic stroke, hospitalisation for heart failure, major bleeding, CV, and all-cause death) and the adjudication process are listed in the Supplementary material online.(7,8,11)”
Mäegdefessel, L., Linde, T., Krapiec, F., Hamilton, K. F., Steinseifer, U., van Ryn, J., Raaz, U., Buerke, M., Werdan, K., & Schlitt, A. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.06.011 · Cited by 52
Use of New Oral Anticoagulants in Antiphospholipid Syndrome
Arachchillage, D. J., & Cohen, H. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-013-0331-5 · Cited by 52
The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation
Murphy, A., Banerjee, A., BREITHARDT, G. E., Camm, A. J., Commerford, P., Freedman, B., González-Hermosillo, J. A., Halperin, J. L., Lau, C., Perel, P., et al. (2017) · Global Heart · doi:10.1016/j.gheart.2017.01.015 · Cited by 53
“4, 2017 December 2017: 273-284 when the time in therapeutic range is reasonably well managed, and has no advantage over warfarin in terms of major bleeding [49,50].”
BackgroundReddy, V. Y., Akehurst, R. L., Armstrong, S. O., Amorosi, S. L., Brereton, N. J., Hertz, D. S., & Holmes, D. R. (2016) · EP Europace · doi:10.1093/europace/euv412 · Cited by 51
Lin, L., Lim, W. S., Zhou, H. J., Khoo, A. L., Tan, K. T., Chew, A. P., Foo, D. C. G., Chin, J. J., & Lim, B. P. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.09.008 · Cited by 52
Oral Anticoagulant Therapy in Atrial Fibrillation Patients at High Stroke and Bleeding Risk
Potpara, T., & Lip, G. Y. H. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.07.003 · Cited by 52
Pircher, J., Fochler, F., Czermak, T., Mannell, H., Kraemer, B. F., Wörnle, M., Sparatore, A., Soldato, P. D., Pohl, U., & Krötz, F. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300627 · Cited by 52
Atrial fibrillation genetic risk differentiates cardioembolic stroke from other stroke subtypes
Pulit, S. L., Weng, L.-C. C., McArdle, P. F., Trinquart, L., Choi, S. H., Mitchell, B. D., Rosand, J. M., de Bakker, P. I. W., Benjamin, E. J., Ellinor, P. T., et al. (2018) · Neurology Genetics · doi:10.1212/nxg.0000000000000293 · Cited by 51
Benz, A. P., Hijazi, Z., Lindbäck, J., Connolly, S. J., Eikelboom, J. W., Oldgren, J., Siegbahn, A. G., & Wallentin, L. C. (2021) · Circulation · doi:10.1161/circulationaha.120.053100 · Cited by 54
Association of cyclooxygenase-2 genetic variant with cardiovascular disease
Ross, S., Eikelboom, J. W., Anand, S. S., Eriksson, N., Gerstein, H. C., Mehta, S. R., Connolly, S. J., Rose, L. M., Ridker, P. M., Wallentin, L. C., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu168 · Cited by 50
LaHaye, S. A., Gibbens, S. L., Ball, D. G. A., Day, A. G., Olesen, J. B., & Skanes, A. C. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs167 · Cited by 50
New Appraisal of Atrial Fibrillation Burden and Stroke Prevention
PASSMAN, R. S., & Bernstein, R. A. (2016) · Stroke · doi:10.1161/strokeaha.115.009930 · Cited by 52
Pfeilschifter, W., Luger, S., Brunkhorst, R., Lindhoff‐Last, E., & Foerch, C. (2013) · Cerebrovascular Diseases · doi:10.1159/000352062 · Cited by 49
Stroke Prevention: Managing Modifiable Risk Factors
Legge, S. D., Koch, G., Diomedi, M., Stanzione, P., & Sallustio, F. (2012) · Stroke Research and Treatment · doi:10.1155/2012/391538 · Cited by 51
“Analysis of an additional arm of the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE A) in patients unsuitable for vitamin K antagonists therapy [32] showed superiority of combination therapy with aspirin and clopidogrel over aspirin alone in reducing the rate of stroke…”
Ng, K. H., Hart, R. G., & Eikelboom, J. W. (2013) · Cardiology and Therapy · doi:10.1007/s40119-013-0019-y · Cited by 49
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction
Bonaca, M. P., Goto, S., Bhatt, D. L., Steg, P. G., Storey, R. F., Cohen, M. C., Goodrich, E. L., Mauri, L., Ophuis, T. O., Ruda, M., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.024637 · Cited by 52
Leentjens, J., Peters, M. J. L., Esselink, A. C., Smulders, Y. M., & Kramers, C. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13340 · Cited by 49
Nielsen, P. B., Skjøth, F., Søgaard, M., Kjældgaard, J. N., Lip, G. Y. H., & Larsen, T. B. (2019) · Stroke · doi:10.1161/strokeaha.118.023797 · Cited by 49
Activation of Hemostasis and Decline in Cognitive Function in Older People
Stott, D. J., Robertson, M., Rumley, A., Welsh, P. I., Sattar, N. A., Packard, C. J., Shepherd, J., Trompet, S., Westendorp, R. G. J., de Craen, A. J. M., et al. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.199448 · Cited by 49
Effect of Addition of Clopidogrel to Aspirin on Mortality: Systematic Review of Randomized Trials
Palacio, S., Hart, R. G., Pearce, L. A., & Benavente, O. R. (2012) · Stroke · doi:10.1161/strokeaha.112.656173 · Cited by 47
Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation
Bernard, A., Fauchier, L., Pellegrin, C., Clementy, N., Etienne, C. S., Banerjee, A., Naudin, D., & Angoulvant, D. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-04-0351 · Cited by 55
“In AF patients for whom OAC was unsuitable, it was found that the addition of clopidogrel to aspirin reduced the risk of vascular events, especially stroke and increased the risk of major haemorrhage (13).”
BackgroundII Diretrizes Brasileiras de Fibrilação Atrial
Magalhães, L., Figueiredo, M., Cintra, F., Eb, S., Kuniyoshi, R. R., Teixeira, R., Filho, A. L., d’Ávila, A., de Paola, A., Kalil, C., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160055 · Cited by 51
Andersen, L. V., Lip, G. Y. H., Lindholt, J. S., & Frost, L. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12181 · Cited by 47
Bivalirudin: a review of the pharmacology and clinical application
Car, D. A. V. D., Rao, S. V., & Ohman, E. M. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.158 · Cited by 47
Paikin, J. S., Wright, D. S., & Eikelboom, J. W. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.01.007 · Cited by 46
Warfarin and atrial fibrillation: from ideal to real the warfarin affaire
Molteni, M., & Cimminiello, C. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-5 · Cited by 48
Lip, G. Y. H., Al‐Khatib, S. M., Cosío, F. G., Banerjee, A., Savelieva, I., Ruskin, J. N., Blendea, D. C., Nattel, S., Bono, J. D., Conroy, J., et al. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001179 · Cited by 48
Meincke, F., Schmidt-Salzmann, M., Kreidel, F., Kück, K., & Bergmann, M. (2013) · EuroIntervention · doi:10.4244/eijv9i4a75 · Cited by 47
Risk stratification for stroke in atrial fibrillation: a critique
Killu, A. M., Granger, C. B., & Gersh, B. J. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy731 · Cited by 50
“to take anticoagulants, aspirin and clopidogrel combination therapy has been shown to reduce the stroke risk though with significantly elevated bleeding risk.(38) In such patients, LAA occlusion procedures could be considered.”
2020 Clinical practice guidelines for Hypertrophic cardiomyopathy
Габрусенко, С. А., Gudkova, A. Y., Koziolova, N. A., Alexandrova, S. А., Berseneva, M., Гордеев, М. Л., Sl, D., Zaklyazminskaya, E. V., Irtyuga, O. B., Kaplunova, V. Y., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4541 · Cited by 56
Ito, M., Kaikita, K., Sueta, D., Ishii, M., Oimatsu, Y., Arima, Y., Iwashita, S., Takahashi, A., Hoshiyama, T., Kanazawa, H., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002744 · Cited by 46
Liu, Y., Zheng, Y. Z., Karataş, H., Wang, X., Foerch, C., Lo, E. H., & van Leyen, K. (2017) · Stroke · doi:10.1161/strokeaha.116.014790 · Cited by 46
Atrial Fibrillation and Acute Myocardial Infarction: Antithrombotic Therapy and Outcomes
Lópes, R. D., Li, L., Granger, C. B., Wang, T. Y., Foody, J. M., Funk, M., Peterson, E. D., & Alexander, K. P. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.04.006 · Cited by 45
Detection of Atrial Fibrillation After Stroke and the Risk of Recurrent Stroke
Kamel, H., Johnson, D. R., Hegde, M., Go, A. S., Sidney, S., Sorel, M. E., Hills, N. K., & Johnston, S. C. (2011) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2011.03.008 · Cited by 45
Primary and Secondary Prevention of Ischemic Stroke
Paciaroni, M., & Bogousslavsky, J. (2010) · European Neurology · doi:10.1159/000285183 · Cited by 44
Attena, E., Mazzone, C., Esposito, F., Parisi, V., Bancone, C., Rago, A., Nigro, G., Sangiuolo, R., D’Onofrio, A., & Russo, V. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1615261 · Cited by 45
Dabigatran Treatment of Acute Noncardioembolic Ischemic Stroke
Butcher, K., Ng, K., Sheridan, P., Field, T. S., Coutts, S. B., Siddiqui, M., Gioia, L. C., Buck, B. H., Hill, M. D., Miller, J., et al. (2020) · Stroke · doi:10.1161/strokeaha.119.027569 · Cited by 46
Prevention of Cardioembolic Stroke
Freeman, W. D., & Aguilar, M. I. (2011) · Neurotherapeutics · doi:10.1007/s13311-011-0048-y · Cited by 45
Lewis, J. P., Voora, D., & Beitelshees, A. L. (2015) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s52900 · Cited by 44
Chinese guidelines for the diagnosis and management of atrial fibrillation
Ma, C., Wu, S., Liu, S., & Han, Y. (2024) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.14920 · Cited by 48
Rasmussen, L. H., Larsen, T. B., Due, K. M., Tjønneland, A. M., Overvad, K., & Lip, G. Y. H. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04308.x · Cited by 44
Cleland, J. G. F., Coletta, A. P., Yassin, A., Buga, L., Torabi, A., & Clark, A. L. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp162 · Cited by 44
Waksman, R., & PENDYALA, L. K. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.11.011 · Cited by 45
Atrial Fibrillation in Congestive Heart Failure
Seiler, J., & Stevenson, W. G. (2009) · Cardiology in Review · doi:10.1097/crd.0b013e3181c21cff · Cited by 44
The pharmacogenetics of antiplatelet agents: towards personalized therapy?
Ahmad, T. A., Voora, D., & Becker, R. C. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.111 · Cited by 44
Preventing Stroke in Patients With Chronic Kidney Disease and Atrial Fibrillation
Reinecke, H., Engelbertz, C. M., & Schäbitz, W. (2013) · Stroke · doi:10.1161/strokeaha.113.001701 · Cited by 44
Meta-Analysis of Randomized Controlled Trials on the Risk of Bleeding With Dabigatran
Bloom, B. J., Filion, K. B., Atallah, R., & Eisenberg, M. J. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.11.049 · Cited by 43
Ahmad, Y., Lip, G. Y. H., & Apostolakis, S. Z. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.148 · Cited by 43
Evidence Gaps in the Era of Non–Vitamin K Oral Anticoagulants
Aronis, K. N., & Hylek, E. M. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007338 · Cited by 45
Verheugt, F. W. A., Gao, H., Almahmeed, W. A., Ambrosio, G., Angchaisuksiri, P., Atar, D., Bassand, J., Camm, A. J., Cools, F. J. S., Eikelboom, J. W., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx730 · Cited by 43
“The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE)-A study showed in anticoagulation-ineligible patients that the combination of clopidogrel and aspirin was more effective than aspirin alone, but it caused more major bleeding, especially intracranial bleeding.(25) Howe…”
MethodIncreased Risk of Bleeding in Patients on Clopidogrel Therapy After Drug-Eluting Stents Implantation
Tsai, T. T., Ho, P. M., Xu, S., Powers, J. D., Carroll, N. M., Shetterly, S. M., Maddox, T. M., Rumsfeld, J. S., Margolis, K. L., Go, A. S., et al. (2010) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.109.919001 · Cited by 43
Bousser, M. (2012) · Frontiers of Medicine · doi:10.1007/s11684-012-0178-6 · Cited by 44
Lu, S.-Y., Tsai, C.-Y., Lin, L.-Y., & Lu, S.-N. (2016) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2016.02.010 · Cited by 42
Lagoutte‐Renosi, J., Poupon, J. L., Girard, A., Montange, D., & Davani, S. (2018) · Journal of Chromatography B · doi:10.1016/j.jchromb.2018.09.026 · Cited by 42
Treatment Approaches to Lacunar Stroke
Das, A. S., Regenhardt, R. W., Feske, S. K., & Gurol, M. E. (2019) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2019.05.004 · Cited by 44
Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia
VASCERN-HHT, Shovlin, C. L., Millar, C. M., Droege, F., Kjeldsen, A. D., Manfredi, G., Suppressa, P., Ugolini, S., Coote, N., Fialla, A. D., et al. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1179-1 · Cited by 42
Tailoring Antiplatelet Therapy Based on Pharmacogenomics
Bhatt, D. L. (2009) · JAMA · doi:10.1001/jama.2009.1249 · Cited by 42
New anticoagulants – promising and failed developments
Harenberg, J., Marx, S., Krejczy, M., & Wehling, M. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01578.x · Cited by 41
New anticoagulant treatments to protect against stroke in atrial fibrillation
Potpara, T., Lip, G. Y. H., & Apostolakis, S. Z. (2012) · Heart · doi:10.1136/heartjnl-2012-301841 · Cited by 41
Valgimigli, M., Park, S., Kim, H.-S., Park, K. W., Park, D., Tricoci, P., & Ferrante, G. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.03.047 · Cited by 41
Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents
Bassand, J. (2012) · EP Europace · doi:10.1093/europace/eur263 · Cited by 42
Kaku, B. (2013) · Journal of Medical Case Reports · doi:10.1186/1752-1947-7-238 · Cited by 41
Alam, M., Bandeali, S. J., Shahzad, S. A., & Lakkis, N. M. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.8 · Cited by 41
Renoux, C., Patenaude, V., & Suissa, S. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001402 · Cited by 41
Meeting the Unmet Needs in Anticoagulant Therapy
Weitz, J. I. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01461.x · Cited by 42
Moner-Banet, T., Alberio, L., & Bart, P. (2020) · Hämostaseologie · doi:10.1055/a-1113-0655 · Cited by 41
Jung, B. C., Kim, N. H., Nam, G. B., Park, H. W., On, Y. K., Lee, Y. S., Lim, H. E., Joung, B., Cha, T. J., Hwang, G., et al. (2015) · Korean Circulation Journal · doi:10.4070/kcj.2015.45.1.9 · Cited by 40
AbuDagga, A., Stephenson, J. J., Fu, A.-C., Kwong, W. J., Tan, H., & Weintraub, W. S. (2014) · BMC Health Services Research · doi:10.1186/1472-6963-14-310 · Cited by 40
Clemens, A., Noack, H., Brueckmann, M., & Lip, G. Y. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099276 · Cited by 41
Antiplatelet agents, warfarin, and epidemic intracranial hemorrhage
Siracuse, J. J., Robich, M. P., Gautam, S., Kasper, E. M., Moorman, D. W., & Hauser, C. J. (2010) · Surgery · doi:10.1016/j.surg.2010.07.014 · Cited by 40
Assiri, A. M., Al-Majzoub, O., Kanaan, A. O., Donovan, J. L., & Silva, M. J. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.05.011 · Cited by 40
Metadata
- Authors
- The ACTIVE Investigators
- Affiliations
- Population Health Research Institute (CA)
- Corresponding author
- The ACTIVE Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-05-14
- Volume
- 360
- Issue
- 20
- Pages
- 2066-2078
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2113089341
- Cited by
- 2,102
- References
- 25
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 25 · 2023: 19 · 2022: 23 · 2021: 55 · 2020: 65 · 2019: 73 · 2018: 75 · 2017: 115 · 2016: 166 · 2015: 205 · 2014: 209 · 2013: 264 · 2012: 286
- FWCI
- 168.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- Own your potential (DEAKIN) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- clopidogrel, aspirin, atrial fibrillation, stroke prevention, antiplatelet therapy, vitamin K antagonists, myocardial infarction, major bleeding, vascular events, systemic embolism, anticoagulation alternatives, bleeding risk, stroke risk reduction, quality of life, cost-effectiveness
- MeSH terms
- Clopidogrel, Aged, Aspirin, Atrial Fibrillation, Double-Blind Method, Drug Therapy, Combination, Embolism, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Risk, Ticlopidine, Vascular Diseases, Vitamin K, Incidence, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
